- FDA approves tablet formulation of Evrysdi® (risdiplam) for spinal muscular atrophy treatment - Tablet provides comparable systemic exposure, efficacy, and safety as the oral solution - Offers room temperature stability, eliminating the need for refrigeration - Approved for patients aged 2 years and older - New option expected to be available in the coming weeks